Phase 3 Readout

VCEL: Phase 3 Topline: A Prospective, Open-label, Randomized, Concurrent Active-controlled, Longitudinal, Multicenter, Phas

Name: Phase 3 Topline: A Prospective, Open-label, Randomized, Concurrent Active-controlled, Longitudinal, Multicenter, Phas
Start: 2030-02-01
End: 2030-02-01

February 1, 2030 · maci. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: February 1, 2030
Company: Vericel Corp (VCEL)
Drug: maci

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Prospective, Open-label, Randomized, Concurrent Active-controlled, Longitudinal, Multicenter, Phas

February 1, 2030

VCEL overview →

Company: Vericel Corp (VCEL)
Drug: maci
Indication: Chondral Defect; Articular Cartilage Defect; Osteochondritis Dissecans (OCD)